Acromegalic patients lost to follow-up: a pilot study
- 220 Downloads
Approximately 50 % of all acromegalic patients will require lifelong medical treatment to normalize mortality rates and reduce morbidity. Thus, adherence to therapy is essential to achieve treatment goals. To date, no study has evaluated the frequency and reasons for loss to follow-up in the acromegalic population. The current study aimed at evaluating the frequency of acromegalic patient loss to follow-up in three reference centers and the reasons responsible for their low compliance with treatment. All of the files for the acromegalic patients in the three centers were reviewed. Those patients, who had not followed up with the hospital for more than a year, were contacted via phone and/or mail and invited to participate. Patients who agreed to participate were interviewed, and blood samples were collected. A total of 239 files were reviewed; from these 42 patients (17.6 %) were identified who were lost to follow-up. It was possible to contact 27 of these patients, 10 of whom did not attend the appointments for more than one time and 17 of whom agreed to participate in the study. Fifteen of these 17 patients had active disease (88.2 %), and all of the patients restarted treatment in the original centers. The main reason for loss to follow-up was an absence of symptoms. High-quality follow-up is important in acromegaly to successfully achieve the aims of the treatment. An active search for patients may allow the resumption of treatment in a significant proportion of these cases, contributing to reduced morbidity and mortality in this patient population.
KeywordsAcromegaly Compliance Follow-up Chronic disease
This work is supported by a grant from Novartis Biociências S.A.
Conflict of interest
MRG received grant support from Novartis Biociências S.A and Pfizer and speaker fees from Novartis Biociências, Pfizer and Ipsen. RNC is an employee of Novartis Biociências S.A in Brazil.
The authors declare that this study complies with the current laws of Brazil.
- 4.Vieira Neto L, Abucham J, Araujo LA, Boguszewski CL, Bronstein MD, Czepielewski M, Jallad RS, Musolino NR, Naves LA, Ribeiro-Oliveira A Junior, Ribeiro-Oliveira A Jr, Vilar L, Faria Mdos S, Gadelha MR (2011) Recommendations of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil. Arq Bras Endocrinol Metabol 55(2):91–105PubMedCrossRefGoogle Scholar
- 12.Tutuncu, Y., Berker, D., Isik, S., Ozuguz, U., Akbaba, G., Kucukler, F.K., Aydin, Y., Guler, S.: Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary Aug 25 Epub ahead of print (2011)Google Scholar
- 17.Vilar L, Azevedo MF, Naves LA, Casulari LA, Albuquerque JL, Montenegro RM, Montenegro RM Jr, Figueiredo P, Nascimento GC, Faria MS (2011) Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. Pituitary 14(2):148–156PubMedCrossRefGoogle Scholar
- 20.Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342(16):1171–1177PubMedCrossRefGoogle Scholar
- 22.Muller, R., Kallikorm, R., Polluste, K., Lember, M.: Compliance with treatment of rheumatoid arthritis. Rheumatol Int Sep 29 Epub ahead of print (2011)Google Scholar
- 25.Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151(4):439–446PubMedCrossRefGoogle Scholar